Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry

American Heart Journal

Volumn 168, Issue 2, 2014, Pages 160-167

  Steinberg, Benjamin A ^a,b   Blanco, Rosalia G ^b   Ollis, Donna ^b   Kim, Sunghee ^b   Holmes, Dajuanicia N ^b   Kowey, Peter R ^c   Fonarow, Gregg C ^d   Ansell, Jack ^e   Gersh, Bernard ^f   Go, Alan S ^g   Hylek, Elaine ^h   Mahaffey, Kenneth W ⁱ   Thomas, Laine ^b   Chang, Paul ^j   Peterson, Eric D ^a,b   Piccini, Jonathan P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g KAISER PERMANENTE   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; ANTICOAGULANT AGENT; NON VITAMIN K ORAL ANTICOAGULANT; UNCLASSIFIED DRUG;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL PRACTICE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ADULT; CARDIOVASCULAR DISEASE; MULTICENTER STUDY; OUTPATIENT CARE; REGISTER; YOUNG ADULT;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; FACTOR XA; HUMANS; OBSERVATIONAL STUDY AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; REGISTRIES; VENTRICULAR REMODELING;

EID: 84905097597     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.04.005     Document Type: Article

References (36)

1. P.A. Wolf, J.B. Mitchell, and C.S. Baker et al. Impact of atrial fibrillation on mortality, stroke, and medical costs Arch Intern Med 158 3 1998 229 234
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
3. M.D. Ezekowitz, and J.A. Levine Preventing stroke in patients with atrial fibrillation JAMA 281 19 1999 1830 1835
4. R.G. Hart, O. Benavente, and R. McBride et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 7 1999 492 501
5. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 12 2007 857 867
6. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
7. S.J. Connolly, J. Eikelboom, and C. Joyner et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 9 2011 806 817
8. C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
9. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
10. R.P. Giugliano, C.T. Ruff, and E. Braunwald et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 22 2013 2093 2104
11. J.P. Piccini, E.S. Fraulo, and J.E. Ansell et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 4 2011 606 612 e1
12. M.W. Cullen, S. Kim, and J.P. Piccini Sr. et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry Circ Cardiovasc Qual Outcomes 6 4 2013 461 469
13. E.L. Fosbol, D.N. Holmes, and J.P. Piccini et al. Provider specialty and atrial fibrillation treatment strategies in united states community practice: findings from the ORBIT-AF registry J Am Heart Assoc 2 4 2013 e000110
14. P.L. Hess, S. Kim, and J.P. Piccini et al. Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation Am J Med 126 7 2013 625 632 e1
15. B.A. Steinberg, D.N. Holmes, and M.D. Ezekowitz et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry Am Heart J 165 4 2013 622 629
16. B.A. Steinberg, D.N. Holmes, and J.P. Piccini et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation J Am Heart Assoc 2 6 2013 e000535
17. B.A. Steinberg, S. Kim, and J.P. Piccini et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry Circulation 128 7 2013 721 728
18. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 4 2005 692 694
19. B.G. Hammill, A.F. Hernandez, and E.D. Peterson et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers Am Heart J 157 6 2009 995 1000
20. A.F. Hernandez, B.G. Hammill, and E.D. Peterson et al. Relationships between emerging measures of heart failure processes of care and clinical outcomes Am Heart J 159 3 2010 406 413
21. D.M. Siegal, and A. Cuker Reversal of novel oral anticoagulants in patients with major bleeding J Thromb Thrombolysis 35 3 2013 391 398
22. G. Lu, F.R. DeGuzman, and S.J. Hollenbach et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 4 2013 446 451
23. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 14 2011 1573 1579
24. C.K. Enders Applied missing data analysis 2010 Guilford Press
25. R.J.A. Little, and D.B. Rubin Statistical analysis with missing data 2nd ed. 2002 John Wiley & Sones New York
26. D.B. Rubin Inference and missing data Biometrika 63 1976 581 592
27. G.I. Barbash, J. Reiner, and H.D. White et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries J Am Coll Cardiol 26 5 1995 1222 1229
28. G.Y. Lip, T.B. Larsen, and F. Skjoth et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 8 2012 738 746
29. C.T. Ruff, R.P. Giugliano, and E. Braunwald et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 2013 10.1016/S0140-6736(13)62343-0
30. D. Lakkireddy, Y.M. Reddy, and L. Di Biase et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 59 13 2012 1168 1174
31. D. Lakkireddy, Y.M. Reddy, and L. Di Biase et al. Feasibility & safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 63 10 2014 982 988
32. M.R. Southworth, M.E. Reichman, and E.F. Unger Dabigatran and postmarketing reports of bleeding N Engl J Med 368 14 2013 1272 1274
33. T.B. Larsen, L.H. Rasmussen, and F. Skjoth et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study J Am Coll Cardiol 61 22 2013 2264 2273
34. M.V. Huisman, G.Y. Lip, and H.C. Diener et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation Am Heart J 167 3 2014 329 334
35. A.K. Kakkar, I. Mueller, and J.P. Bassand et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry PLoS One 8 5 2013 e63479
36. P.S. Chan, W.J. Oetgen, and D. Buchanan et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program J Am Coll Cardiol 56 1 2010 8 14